
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health is supported by a strong 2Q beat and raise, with revenue of $1,368M, adjusted EBITDA of $288M, and adjusted diluted EPS of $0.34 all topping consensus while gross margin expanded to ~57.7%. Its outlook is strengthened by accelerating demand in Zenrelia, Quattro, and Befrena, plus management’s confidence in a Next Wave innovation pipeline with five to six blockbuster potential approvals and $2B+ peak sales potential. The raised FY26 guidance for revenue, EBITDA, and EPS, along with price increases already visible in pet health and farm animal markets, suggests improving execution, margin expansion, and continued deleveraging.
Bears say
Elanco Animal Health is facing a negative fundamental setup as unfavorable regulatory and pipeline developments, along with differentiated competitor approvals, could weaken investor confidence and pressure future growth. Slower adoption of its 7 key blockbusters, rising cannibalization of existing products, and commoditization in K9 derm or K9 parasiticide markets may depress sales and EPS growth below expectations, while products such as Flea and worm chewable for dogs, Interceptor Plus, and Drontal Family appear vulnerable to share loss. Further uncertainty around product mix transition, pipeline execution, operational improvement plans, and weather, disease, and political risks adds to the downside as an independent company.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Elanco Animal Health Inc (ELAN) Forecast
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares